|Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer||
||1873||Female||18 Years and older (Adult, Senior)||NCT00262847||NCI-2009-00590
|September 2005||November 2010||April 2015||December 7, 2005||November 28, 2017||September 18, 2013||
|2||NCT02766582||Recruiting||Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer||
||30||Female||18 Years and older (Adult, Senior)||NCT02766582||Uyar 25680 IIT Merck||October 2016||December 2020||December 2022||May 10, 2016||November 18, 2016||
† Study has passed its completion date and status has not been verified in more than two years.